Citigroup Faces Lawsuit Over Alleged Sexual Harassment by Top Wealth Executive 
NTSB Opens Investigation Into Waymo Robotaxis After School Bus Safety Violations in Texas 
Trump Lawsuit Against JPMorgan Signals Rising Tensions Between Wall Street and the White House 
Noble Corporation Secures $1.3 Billion in New Contracts, Strengthening Offshore Drilling Backlog 
Tesla Loses Ground in Europe as BYD Accelerates EV Market Share in 2025 
Samsung Set to Begin HBM4 Production for Nvidia and AMD 
Shell Plc Downgraded by RBC as Market Headwinds Pressure Valuation 
ANTA Sports to Acquire Major Stake in Puma in €1.5 Billion Deal, Signaling Strategic Revival 
Micron to Expand Memory Chip Manufacturing Capacity in Singapore Amid Global Shortage 
Zijin Mining Shares Hit Record High on $4 Billion Allied Gold Acquisition 
LVMH Investors Watch Earnings Closely as Luxury Recovery Faces New Challenges 
California Governor Gavin Newsom Launches Review Into Alleged TikTok Content Suppression After U.S. Ownership Deal 
UK Politicians Call for Full Competition Review of Netflix’s Warner Bros Discovery Deal 
ASML’s EUV Monopoly Powers the Global AI Chip Boom 
Microsoft Wins Approval to Build 15 New Data Centers in Wisconsin 
RESEARCH TRIANGLE PARK, N.C., May 16, 2017 -- G1 Therapeutics, Inc., a clinical-stage oncology company, today announced the pricing of its initial public offering of 7,000,000 shares of common stock at a public offering price of $15.00 per share for aggregate gross proceeds of $105,000,000. In addition, G1 Therapeutics has granted the underwriters a 30-day option to purchase up to 1,050,000 additional shares of its common stock at the initial public offering price. The shares are scheduled to begin trading on The NASDAQ Global Select Market on May 17, 2017 under the ticker symbol “GTHX.”
J.P. Morgan Securities LLC and Cowen and Company, LLC are acting as joint book-running managers for the offering. Needham & Company, LLC and Wedbush Securities Inc. are acting as co-managers for the offering.
A registration statement relating to these securities has been filed with and was declared effective by the Securities and Exchange Commission on May 16, 2017. The offering will be made only by means of a prospectus. A copy of the final prospectus relating to the offering will be filed with the Securities and Exchange Commission and may be obtained, when available, from J.P. Morgan Securities LLC, c/o Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, NY 11717, or by telephone at (866) 803-9204; or Cowen and Company, LLC, c/o Broadridge Financial Services, 1155 Long Island Avenue, Edgewood, NY, 11717, Attn: Prospectus Department, or by calling (631) 274-2806 or by faxing (631) 254-7140.
This press release shall not constitute an offer to sell or a solicitation of an offer to buy, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.
About G1 Therapeutics, Inc.
G1 Therapeutics is a clinical-stage biopharmaceutical company developing novel, small-molecule therapies that address significant unmet needs in the treatment of cancer. The company is advancing a pipeline of potential best-in-class and first-in-class drug candidates in multiple oncology indications. G1 is based in Research Triangle Park, NC.
Contacts Investors: Robert Uhl Westwicke Partners 858-356-5932 [email protected] Media: Laura Bagby 6 Degrees Communications 312-448-8098 [email protected]
